WALTHAM, Mass., June 26 /PRNewswire/ -- ImmuLogic Pharmaceutical
Corporation (Nasdaq: IMUL) announced today that it will not proceed with a
planned clinical trial of the ALLERVAX(R) RAGWEED product candidate originally
scheduled for July 1997. The Company received a request from the FDA for
additional data which would be needed prior to the initiation of its planned
clinical trial. Because the trial must be conducted in the summer ragweed
season, the additional time required to respond to the FDA request will delay
the potential initiation of the study until the summer of 1998.
"Management was disappointed to have received these requests so late in
the discussion process," said J. Joseph Marr, M.D., Chief Operating Officer of
ImmuLogic Pharmaceutical Corporation. "We welcome the opportunity to assist
the FDA with its review of the program; however, the time is now too short to
permit us to respond and initiate a trial before the ragweed season. We will
continue our dialogue with the FDA regarding this clinical hold on the
ALLERVAX RAGWEED program."
ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company,
located in Waltham, Massachusetts, which creates, develops, and intends to
market products to treat diseases of the immune system. The Company is
developing treatments for allergies, autoimmune diseases and substance abuse.
The Company's press releases are available on the Internet at
http://www.prnewswire.com or by fax through Company News on Call at 800-758-5804,
ext. 114501.
This press release contains forward-looking statements that involve a
number of risks and uncertainties. Among the most important factors that
could cause actual results to differ materially from those indicated by such
forward-looking statements are delays in product development, failure to
obtain required regulatory approvals, and the risk factors detailed in the
company's Annual Report on Form 10-K for the year ended December 31, 1996.
SOURCE ImmuLogic Pharmaceutical Corp.
back to top
